Scholtz & Company LLC Sells 8,385 Shares of Masimo Co. (MASI)

Share on StockTwits

Scholtz & Company LLC decreased its holdings in shares of Masimo Co. (NASDAQ:MASI) by 16.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,075 shares of the medical equipment provider’s stock after selling 8,385 shares during the period. Masimo makes up 3.9% of Scholtz & Company LLC’s portfolio, making the stock its 12th biggest holding. Scholtz & Company LLC owned 0.08% of Masimo worth $4,518,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Bogart Wealth LLC boosted its holdings in shares of Masimo by 13.7% in the fourth quarter. Bogart Wealth LLC now owns 1,161 shares of the medical equipment provider’s stock worth $124,000 after buying an additional 140 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Masimo by 3.1% in the fourth quarter. State of Alaska Department of Revenue now owns 5,693 shares of the medical equipment provider’s stock worth $611,000 after purchasing an additional 171 shares in the last quarter. Diversified Trust Co lifted its position in shares of Masimo by 13.6% in the fourth quarter. Diversified Trust Co now owns 2,298 shares of the medical equipment provider’s stock worth $247,000 after purchasing an additional 275 shares in the last quarter. Cardinal Capital Management lifted its position in shares of Masimo by 2.0% in the fourth quarter. Cardinal Capital Management now owns 15,353 shares of the medical equipment provider’s stock worth $1,648,000 after purchasing an additional 303 shares in the last quarter. Finally, Strs Ohio lifted its position in shares of Masimo by 10.5% in the fourth quarter. Strs Ohio now owns 3,543 shares of the medical equipment provider’s stock worth $380,000 after purchasing an additional 337 shares in the last quarter. Institutional investors own 87.36% of the company’s stock.

In other news, COO Anand Sampath sold 30,000 shares of the business’s stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $115.00, for a total value of $3,450,000.00. Following the sale, the chief operating officer now owns 42,518 shares in the company, valued at approximately $4,889,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $110.90, for a total transaction of $221,800.00. The disclosure for this sale can be found here. Insiders have sold 68,000 shares of company stock worth $7,691,800 in the last quarter. Corporate insiders own 12.60% of the company’s stock.

Shares of Masimo stock opened at $128.43 on Thursday. Masimo Co. has a 1 year low of $81.56 and a 1 year high of $130.00. The firm has a market capitalization of $6.88 billion, a PE ratio of 52.42, a P/E/G ratio of 2.70 and a beta of 1.07.

Several equities analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $139.00 price objective on shares of Masimo in a research report on Friday, February 1st. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 31st. Zacks Investment Research raised shares of Masimo from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Piper Jaffray Companies raised shares of Masimo from a “neutral” rating to an “overweight” rating and set a $120.00 price target on the stock in a research report on Wednesday, December 19th. Finally, UBS Group assumed coverage on shares of Masimo in a research report on Tuesday, November 27th. They issued a “buy” rating and a $137.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Masimo has a consensus rating of “Buy” and an average target price of $121.86.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Highlight Press and is the sole property of of Highlight Press. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://highlightpress.com/2019/02/14/scholtz-company-llc-has-4-52-million-holdings-in-masimo-co-masi.html.

Masimo Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Article: NASDAQ Stock Market Explained

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply